| 영문 | tolerance | 한글 | 내성, 견딤 |
|---|---|---|---|
| 설명 | 1. 비정상적으로 대량의 약물에 대해 독성영향을 받지 않고 견디며 또한 일정량의 약물의 지속적인 사용에 대해서 효과의 감소를 나타내는 능력. 2. 면역학적으로 항원특이적인 무반응 상태. |
||
| 영문 | glucose tolerance test | 한글 | 포도당견딤검사 |
|---|---|---|---|
| 설명 | 포도당견딤 검사란 당뇨병의 진단에 사용되는 검사로 당을 체내에 투여하고 시간 별로 혈액을 채취하여 혈당의 농도를 재어서 고혈당 여부를 조사하는 검사이다. 주로 경구포도당견딤검사(oral glucose tolerance test)를 많이 하는데 이것은 10~16시간의 금식 후에 채혈을 한번 한뒤에 도당 75g을 250~300mL의 물에 녹여 5분에 걸쳐서 마시게 하고 매시간 별로 채혈을 하여 혈당의 농도를 첵크한다. 공복시에 정맥에서 채혈하여 측정한 혈당이 140mg/dL이상이거나 포도당견딤 검사 2시간후의 혈당이 200mg/dL이상일 경우에는 당뇨병으로 진단을 한다. 그러나 이 검사를 실시할 경우에 주의해야 할 점은 검사전 3일간 하루에 150g이상의 탄수화물을 섭취해야 한다는 것과 검사도중에 운동, 흡연 등을 하지 않아야 한다는 것이다. |
||
| AITT | arginine insulin tolerance test; augmented insulin tolerance test |
|---|---|
| ATT | arginine tolerance test; aspirin tolerance time |
| ETT | endotracheal tube; epinephrine tolerance test; exercise tolerance test; exercise treadmill test; ext... |
| LTT | lactose tolerance test; leucine tolerance test; limited treadmill test; lymphocyte transformation te... |
| HCG, hCG | Human Chorionic Gonadotropin; 사람융모성성선자극호르몬 1. Placental Glycoprotein Hormone &nbs... |
| ETT | Exercise Tolerance Test |
|---|---|
| FTQ | Fagerstrom Tolerance Questionnaire |
| FSIGTT | Frequently sampled intravenous glucose tolerance test |
| GTF | Glucose Tolerance Factor |
| 75 g | Glucose Tolerance Test |
| immunologic tolerance | Lack of immune response to antigen. Theories of tolerance induction include clonal deletion and clonal anergy. In clonal deletion, the actual clone of cells is eliminated whereas in clonal anergy the cells are present but nonfunctional. Synonym: immunological tolerance, immunotolerance, nonresponder tolerance. (05 Mar 2000) |
|---|
| immunologic high dose tolerance | Induction of tolerance by exposure to large amounts of protein antigens. (05 Mar 2000) |
|---|---|
| adjuvants, immunologic | Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (freund's adjuvant, bcg, corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (12 Dec 1998) |
| receptors, immunologic | Cell surface molecules on cells of the immune system that specifically bind surface molecules or messenger molecules and trigger changes in the behaviour of cells. Although these receptors were first identified in the immune system, many have important functions elsewhere. (12 Dec 1998) |
| graft enhancement, immunologic | The induction of prolonged survival and growth of allografts of either tumours or normal tissues which would ordinarily be rejected. It may be induced passively by introducing graft-specific antibodies from previously immunised donors, which bind to the graft's surface antigens, masking them from recognition by T-cells; or actively by prior immunization of the recipient with graft antigens which evoke specific antibodies and form antigen-antibody complexes which bind to the antigen receptor sites of the T-cells and block their cytotoxic activity. (12 Dec 1998) |
| monitoring, immunologic | Testing of immune status in the diagnosis and therapy of cancer, immunoproliferative and immunodeficiency disorders, and autoimmune abnormalities. Changes in immune parameters are of special significance before, during and following organ transplantation. Strategies include measurement of tumour antigen and other markers (often by radioimmunoassay), studies of cellular or humoral immunity in cancer aetiology, immunotherapy trials, etc. (12 Dec 1998) |
| contraception, immunologic | Contraceptive methods utilizing immunologic processes. (12 Dec 1998) |
| cytotoxicity, immunologic | The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitised T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. (12 Dec 1998) |
| cytotoxicity tests, immunologic | The demonstration of the cytotoxic effect on a target cell of a lymphocyte, a mediator released by a sensitised lymphocyte, an antibody, or complement. (12 Dec 1998) |
| suppressor factors, immunologic | Proteins, protein complexes, or glycoproteins secreted by suppressor T-cells that inhibit either subsequent T-cells, B-cells, or other immunologic phenomena. Some of these factors have both histocompatibility (I-j) and antigen-specific domains which may be linked by disulfide bridges. They can be elicited by haptens or other antigens and may be mass-produced by hybridomas or monoclones in the laboratory. (12 Dec 1998) |
| desensitization, immunologic | Immunosuppression by the administration of increasing doses of antigen. Though the exact mechanism is not clear, the therapy results in an increase in serum levels of allergen-specific IgG, suppression of specific IgE, and an increase in suppressor T-cell activity. (12 Dec 1998) |
| dose-response relationship, immunologic | A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell. (12 Dec 1998) |
| immunologic | <immunology> Pertaining to immunology. (18 Nov 1997) |
| immunologic and biological factors | A collective grouping for biologically active substances that play a role in the functioning of the immune system and those that show biological or physiological activity. (12 Dec 1998) |
| immunologic capping | The process by which lymphoid cell surface immunoglobulin receptors, when exposed to bivalent anti-ig antibodies, collect in patches and form a cap at one pole of the cell. The caps may then be endocytosed or shed into the environment in the form of antigen-antibody complexes. Capping has also been induced by lectins and antigens. (12 Dec 1998) |
| immunologic deficiency syndromes | Syndromes in which there is a deficiency or defect in the mechanisms of immunity, either cellular or humoral. (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|